secwatch.observer — SEC 8-K summary
======================================

Issuer:     First Tracks Biotherapeutics, Inc. (TRAX)
CIK:        0002091349
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001193125-26-164328
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 3.02, 3.03, 5.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Tracks Biotherapeutics completes spin-off from AnaptysBio and raises ~$80M in private placement
--------------------------------------------------------------------------------

- Spin-off effective April 20, 2026; AnaptysBio holders received one First Tracks share per AnaptysBio share held on April 6 record date.
- Private placement of ~10.5M shares at $13.81: company issued 5.79M shares (~$80M proceeds) and selling stockholder sold 4.71M shares.
- Entered Separation and Distribution and Transition Services Agreements with AnaptysBio to govern asset/liability split and post-spin operations.
- First Tracks received $100M cash and rights to up to $35M in milestone payments from Vanda Pharmaceuticals collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-164328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer